Stockreport

Bicara Therapeutics Q4 Earnings Call Highlights [Yahoo! Finance]

Bicara Therapeutics Inc.  (BCAX) 
PDF metastatic/unresectable HPV-negative HNSCC, and the program has advanced into the Phase III FORTIFY-HN01 study with 1,500 mg selected as the optimal biological dose and [Read more]